17,261 trials
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
Tonsillectomy
Primary: Difference in Number of Days Requiring Rescue Pain Medication — 5.00; 5.75 Days
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants
Sly Syndrome · MPS VII · Mucopolysaccharidosis
Primary: Percent Change From Baseline in uGAG Excretion (LC-MS/MS-DS) at Week 48 — -58.17 percent change — p=< 0.0001
AIDS-Related Hodgkin Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Follicular Lymphoma
Primary: Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only — 1; 0; 3; 0 Participants
Lymphoma
Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients
Constipation Predominant Irritable Bowel Syndrome
Primary: Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline — 1.01; 1.50; 1.54; 1.57 number of bowel movements/week
Gastroesophageal Reflux Disease
Primary: Percent Change From Baseline to Week 8 in Weekly Heartburn Severity Score (WHSS) — -46.026; -48.978; -55.063; -57.969 percentage change in score — p=0.6065
Hematological Malignancies · Leukemia · Lymphoma
Primary: Number of Patients With Overall Survival — 41 Participants
Acute Lung Injury · Sepsis
Primary: Modified Change in Sequential Organ Failure Assessment (mSOFA) Score — -2.96; -3.20 score on a scale
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI) — 46; 25 Participants — p=<0.0001
Atopic Dermatitis
Primary: Absolute Change in Eczema Area and Severity Index (EASI) Score From Baseline (Last Observation Carried Forward [LOCF]) — -0.85; -2.13; -1.09; -2.86 units on a scale…
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Phase I: Confirmation of Recommended Phase II Dose — 3; 1 mg/kg dose
Colorectal Cancer
Primary: PFS Probability Rate at 9 Months in the Dose Escalation Arm — 45; 48; 0; 55 percent probability
Prediabetic State · Non-alcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Matsuda Index — 1.22; 1.04; -0.02; 0.24 unit on a scale — p=0.2483